期刊文献+

紫杉醇与异环磷酰胺治疗妇科恶性肿瘤临床比较研究 被引量:6

Therapeutic effects of Palitaxel and Ifosfamide for malignant gynecological tumors
下载PDF
导出
摘要 目的观察紫杉醇与异环磷酰胺治疗妇科肿瘤的疗效。方法采用紫杉醇治疗妇科恶性肿瘤37例,其中卵巢肿瘤27例,输卵管癌6例,宫颈癌3例,宫内膜癌1例。33例为术后或化疗后复发病例,4例为原发卵巢癌。异环磷酰胺(IFO)为相应时间内复发的37例妇科恶性肿瘤,其中卵巢癌30例,输卵管癌3例,宫颈癌3例,宫内膜癌1例。紫杉醇化疗前61、2 h给预防用药地塞米松、西咪替丁、苯海拉明,化疗前0.5 h给地塞米松+甲氧氯普氨。然后紫杉醇135~150 mg/m2静注3 h(或腹腔灌注),联合卡铂。异环磷酰胺2.0 g+卡铂。结果紫杉醇化疗组与异环磷酰胺总体生存期分别为37个月和25个月。有效率(CR+PR)分别为48.6%与28%,差异有统计学意义(P〈0.001)。化疗毒副反应主要是骨髓抑制与脱发。结论紫杉醇治疗卵巢癌及输卵管癌疗效好,毒副反应较轻。 Objective To compare the therapeutic effects of Palitaxel and lfosfamide for malignant gynecological tumors. Methods In the Palitaxel group, 27 cases had ovarian cancer, 6 had fallopian tube cancer, 3 had cervical can- cer, and 1 had endometrium cancer; 33 cases had been subjected to surgeries or relapsed after chemotherapies, and 4 were primary ovarian cancer. In the ifosfamide group, 30 cases had ovarian cancer, 3 had fallopian tube cancer, 3 had cervical cancer, and 1 had endometrium cancer; all had relapsed after chemotherapies. In the Palitaxel group, Palitaxel ( 135-150 mg/m^2 ) was intravenously or intraperitonially administered once every three weeks in combination with carboplatin(60 mg). In the lfosfamide group, lfosfamide(2.0 g)was administered in combination with carboplatin(60 mg). Antihistaminics and anti-emetic were given prior to Palitaxel. Results The overall median survival time was 25 months in the lfosfamide group and was 37 months in the Palitaxel group (P 〈0.001). The response rate was 28% and 48.6%, respectively ( P 〈 0.001). The major toxic effects were myelosuppression and alopecia. Conclusion Palitaxel is effective in the treatment of advanced gynecological tumors.
出处 《山东大学学报(医学版)》 CAS 北大核心 2007年第11期1153-1155,共3页 Journal of Shandong University:Health Sciences
关键词 卵巢肿瘤 输卵管肿瘤 紫杉醇 异环磷酰胺 Ovarian neoplasms Fallopian tube neoplasms Palitaxel lfosfamide Carboplatin
  • 相关文献

参考文献10

  • 1Hehr T, Classen J, Belka C, et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of headand-neck cancer: a prospective phase Ⅰ/Ⅱ trial[J]. Int J Radiat Oncol Biol Phys, 2005, 61(5):1423-1431.
  • 2Nabell L, Spencer S. Doeetaxel with concurrent radiotherapy in head and neck cancer[J]. Semin Oncol, 2003, 30(6): 89-93.
  • 3Ogawa T, Terada A, Hyodo I, et al. A Phase Ⅰ study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head neck [ J ]. Gan To Kagaku Ryoho, 2005, 32 (7) : 977-981.
  • 4Tsukuda M, Mikami Y, Tanigaki Y, et al. Phase itrial of combined chemotherapy with docetaxel, cisplatin, and 5-fluomuracill for patients with locally advanced squamous cell carcinoma of the head and neck[J]. Int J Clin Oncol, 2004, 9(3):161-156.
  • 5Genet D, Cupissol D, Calais G, et al. Docetaxel plus 5-fluomuracill in locally recurrent and/or metastatie squamous cell carcinoma of the head and neck: a phase Ⅱ multicenter study[J]. Am J Clin Oncol, 2004, 27(5) :472-476.
  • 6Thigpen J T, Blessing J A, Ball H, et al. Phase Ⅱ trial of paclitaxel in patients with progressive ovarian carcinoma after platium-based chemotherapy: a gynecologic oncology group study[J]. J Chn Oncol, 2001, 12(5):1748-1753.
  • 7Nabell L, Spencer S. Doeetaxel with concurrent radiotherapy in head and neck cancer[J]. Semin Oncol, 2003, 30(6) : 89-93.
  • 8Kwong D L, Sham J S, Au G K, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study[J]. J Clin Oncol, 2004, 22(13):2643-2653.
  • 9Hennequin C. Association of taxanes and radiotherapy: prechnical and clinical studies[J]. Cancer Radiother, 2004, 8 (1 1) :95-105.
  • 10Ogawa T, Terada A, Hyodo I, et al. A Phase Ⅰ study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck [ J]. Gan To Kagaku Ryoho, 2005, 32(7) :977-981.

同被引文献38

  • 1李素华.紫杉醇治疗妇科恶性肿瘤的护理[J].中国现代药物应用,2009,3(6):177-178. 被引量:5
  • 2杨宇星,程晓伟,俞小元.晚期及复发妇科恶性肿瘤紫杉醇联合化疗36例分析[J].实用临床医药杂志,2005,9(11):89-90. 被引量:2
  • 3张东萍,沈丹萍.紫杉醇的临床应用进展[J].中国药业,2007,16(7):62-64. 被引量:2
  • 4Ozols RF,Bundy BN,Greer BE,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and pa- clitaxel in patients with optimally resected stage III ovarian cancer:a Gynecologic Oncology Group study[J]. J Clin On- cel, 2003,21 (17) : 3194-3200.
  • 5Nabell L,Spencer S. Docetaxel with concurrent radiothera- py in head and neck cancer [J]. Semin Oncol,2013,30 (6) :89-93.
  • 6Guppy AE,Nelstrop AE,Foster T,et al. A phase II study of sequential carbop latin paclitaxel and topotecan in pa- tients with previously untreated advanced ovarian cancer[J]. Br J Cancer, 2004,90 (4) : 810-814.
  • 7Schmitt-sody M, Strieth S, Krasniei S, et al. Neovaschlar- targeting therapy paclitaxel encaosulated in cationic lipo- somes improves antitumoral efficacy[J]. Clin Cancer Res, 2003,9(6) :2335-2341.
  • 8Strieth S,Eichhorm ME,Sauer B,et al. Neovascular tar- geting chemotherpy:encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature [J]. Int J Cancer,2011,12(01 ) : 117-124.
  • 9林银凤.应用紫杉醇治疗妇科恶性肿瘤的临床疗效研究[J]{H}中国保健营养,2012(08):41-42.
  • 10Averineni RK,Shavi GV,Gurram AK. PLGA 50:50 nanoparticles of paclitaxel:development,in vitro anti-tumor activity in BT-549 cells and in vivo evaluation[J].{H}Bulletin of Materials Science,2012,(03):229-230.

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部